+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Drug Delivery: Transdermal Devices

  • PDF Icon

    Report

  • 76 Pages
  • May 2022
  • Region: Global
  • MedDeviceTracker
  • ID: 5019681

In 2021, global sales of transdermal patch products targeting the conditions covered by this analysis totaled nearly $4.9bn, with pain management products accounting for the most sales, followed by neurological disorder management products, cardiovascular disease (CVD)-related products, and hormone replacement therapy (HRT)-related products. Market drivers include the increasing prevalence of CVD, neurological disorders, osteoporosis, menopause, and chronic pain as the population ages; as well as improved patient compliance with patch-based pharmacology compared to oral medication. Limiters include declines in mature market segments, strong competition from oral medications, and generic erosion as brand manufacturers experience patent expiry. This analysis provides a discussion of the sales, competitors, drivers, and limiters of the transdermal drug delivery devices market in the areas of CVD (eg angina pectoris and hypertension), neurological disorders (eg ADHD, major depressive disorder, Alzheimer’s disease, and Parkinson’s disease), HRT (eg menopause and osteoporosis treatment), and pain management (eg fentanyl- and lidocaine-based chronic pain treatment). Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World. The forecast range for this report is 2021-26.

Table of Contents

Executive Summary

i. Transdermal drug delivery devices market
ii. Methodology

1. Transdermal Drug Delivery Technology
1.1 Technology
1.2 Bibliography

2. Transdermal Drug Delivery Systems
2.1 Cardiovascular disease management
2.2 Neurological disorder management
2.3 Hormone replacement therapy
2.4 Pain management
2.5 Bibliography

3. Transdermal Drug Delivery Systems Market
3.1 Regulatory issues
3.2 Cardiovascular disease management
3.3 Neurological disorder management
3.4 Hormone replacement therapy
3.5 Pain management
3.6 Combined market
3.7 Bibliography

  • Appendix: Company Listing

Executive Summary

This chapter provides a discussion of the sales, competitors, drivers, and limiters of the transdermal drug delivery devices market in the areas of cardiovascular disease (CVD; eg angina pectoris and hypertension), neurological disorders (eg attention deficit hyperactivity disorder [ADHD], major depressive disorder [MDD], Alzheimer’s disease, and Parkinson’s disease), hormone replacement therapy (HRT; eg menopause and osteoporosis treatment), and pain management (eg fentanyl- and lidocaine-based chronic pain treatment). Markets covered by this analysis include the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW) markets.